ArticleExperimental hematology & oncology2025
Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy.
Article in Experimental hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cellular senescence and regulated cell death in cancer: mechanisms, cross-regulatory networks and therapeutic implications.Journal of hematology & oncology · 2026Review
- Neutrophil extracellular traps in osteoporosis: mechanistic links to bone remodeling imbalance and therapeutic perspectives.Molecular biology reports · 2026Review
- Licoricidin triggers reactive oxygen species-mediated PANoptosis in human hepatocellular carcinoma cells.International journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTetrahydromagnolol (THM) is a compound isolated from Magnolia officinalis with unique chemical structure and composition. However, its anticancer effect of THM and the underlying molecular mechanisms remain unclear.
methodFirstly, the anticancer effects of THM on different cancer cell lines in vitro were investigated. Subsequently, the antitumor activity of THM was further evaluated in vivo and in vitro using colorectal and lung cancer models. This assessment involved the effects of THM on cell viability, apoptosis, proliferation, cell cycle progression, and tumor growth inhibition. In addition, the anticancer molecular mechanisms of THM were determined by RNA sequencing, western blot, immunohistochemistry, immunofluorescence, CETSA, and SPR. Meanwhile, the effects of THM on organelles were evaluated by measuring endoplasmic reticulum stress, mitochondrial membrane potential damage, reactive oxygen species (ROS), and calcium ion concentration. Finally, the efficacy of THM in combination with conventional anticancer drugs for colorectal cancer treatment was evaluated in vivo.
resultsThe results showed that THM had a significant anticancer activity in colorectal cancer and lung cancer both in vitro and in vivo. THM significantly inhibited cell proliferation and induced PANoptosis-like cell death through GSDME mediated pyroptosis, CASP3 mediated apoptosis, and MLKL mediated necroptosis. In addition, the anticancer potential of THM was also related to elevation of endoplasmic reticulum stress, mitochondrial membrane potential destruction, and increase of ROS and intracellular calcium concentration. Mechanically, we found that THM could directly bind to triplet motif-containing 38 (TRIM38) and induced its upregulation at mRNA and protein levels. Importantly, knockdown of TRIM38 remarkably rescued the anticancer effects of THM and PANoptosis induced by THM treatment, suggesting that TRIM38 played a key role in mediating the antitumor activity of THM. In addition, THM showed significant synergistic therapeutic effects when used in combination with conventional anticancer strategies (Cetuximab, FOLFOX, and FOLFIRI regimens) for colorectal cancer treatment.
conclusionOur data suggest that THM exerts its anticancer potential by inducing TRIM38-dependent PANoptosis and it also has synergistic antitumor effects in combination with conventional anticancer strategies. THM will be a promising candidate drug used alone or in combination with other anticancer regimens for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.